Merck Pays Bristol-Myers $625M In Cancer Treatment IP Row
Merck will pay Bristol-Myers Squibb $625 million to end an ongoing intellectual property battle over an immunotherapy cancer treatment, the companies announced on Friday, ending multiple cases including three lawsuits in...To view the full article, register now.
Already a subscriber? Click here to view full article